Lead Product(s) : Sodium Fluoride,Inapplicable
Therapeutic Area : Dental and Oral Health
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Assessing Gingivitis of 3 Different Dentifrices Compared to a Negative Control.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 25, 2025
Lead Product(s) : Sodium Fluoride,Inapplicable
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KH001,Inapplicable
Therapeutic Area : Dental and Oral Health
Study Phase : Phase II
Sponsor : HysensBio
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 30, 2024
Lead Product(s) : KH001,Inapplicable
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Sponsor : HysensBio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Dental and Oral Health
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 22, 2024
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Meridol,Inapplicable
Therapeutic Area : Dental and Oral Health
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 21, 2024
Lead Product(s) : Meridol,Inapplicable
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AAV2-hAQP1,Inapplicable
Therapeutic Area : Dental and Oral Health
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 09, 2024
Lead Product(s) : AAV2-hAQP1,Inapplicable
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KH001,Inapplicable
Therapeutic Area : Dental and Oral Health
Study Phase : Phase II
Sponsor : The Forsyth Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Study of KH001 in Long-term Relief from Dentin Hypersensitivity
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2024
Lead Product(s) : KH001,Inapplicable
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Sponsor : The Forsyth Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KH001,Inapplicable
Therapeutic Area : Dental and Oral Health
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Efficacy and Safety of KH001 in Patients with Dentin Hypersensitivity
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 20, 2024
Lead Product(s) : KH001,Inapplicable
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AAV2-hAQP1,Inapplicable
Therapeutic Area : Dental and Oral Health
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 03, 2023
Lead Product(s) : AAV2-hAQP1,Inapplicable
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Silver Diamine Fluoride,Inapplicable
Therapeutic Area : Dental and Oral Health
Study Phase : Phase II
Sponsor : University of Washington
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics of Advantage Arrest in Healthy Children 13-Months to 13-Years of Age
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 04, 2023
Lead Product(s) : Silver Diamine Fluoride,Inapplicable
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Sponsor : University of Washington
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorite,Fluoride,Chlorine Dioxide,Disodium Hydrogen Phosphate,Citric Acid
Therapeutic Area : Dental and Oral Health
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2022
Lead Product(s) : Chlorite,Fluoride,Chlorine Dioxide,Disodium Hydrogen Phosphate,Citric Acid
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable